Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
about
Plasma levels of soluble HLA-E and HLA-F at diagnosis may predict overall survival of neuroblastoma patientsThe immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltrationTrial watch: Prognostic and predictive value of the immune infiltrate in cancerThe microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytesNew prognostic markers in neuroblastoma.Myeloid-derived suppressor cells in glioma.Signaling pathways involved in MDSC regulation.Myeloid-derived suppressor cells in immunity and autoimmunity.Targeting of heme oxygenase-1 as a novel immune regulator of neuroblastoma.HMGB1-induced autophagy in Schwann cells promotes neuroblastoma proliferation.Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma.IL-10 and ARG-1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome.Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival.CD4+CD25hiCD127- Treg and CD4+CD45R0+CD49b+LAG3+ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma.HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma.Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma.Innate immune sensor laboratory of genetics and physiology 2 suppresses tumor cell growth and functions as a prognostic marker in neuroblastoma
P2860
Q28304289-B8440AA4-E902-498E-B87D-ED09261A32BFQ34315871-7EA348BA-70B3-4CD4-8FFB-3FC3884A536CQ34346730-99C0D479-0ED5-4BF9-947D-03CCFD420761Q36456483-D5C41D99-5EC4-4C1F-B603-D7ABAC072DE7Q36866183-5D8823EC-8183-4C01-8901-77D415AE66F9Q38088418-12C72F1D-46C5-492B-9B1C-50B1B58324EDQ38161536-8932F32C-3A80-4408-B3C1-380C6BB874D3Q38204175-3EA048FC-9BF6-4582-AA5B-FC9C196F6683Q38509763-377509D2-EBEF-4524-B3F2-68CE38FF7C0EQ38817604-8DE5A1DF-C465-45F9-B56D-4F651CEEB4F1Q38901708-0B38B555-C6EE-4475-A6F9-1FDEEEB35374Q40053162-9A964593-1C82-4EE5-8166-2B5D5088B2FFQ40190430-58454507-736A-431A-895B-6EA0736EE816Q41579154-3FF82DED-8C4D-41A3-B681-AB2CE0EB5041Q42333778-D933E4F4-129C-4B3C-A690-09FA2CB6098AQ42829235-E5BEA59B-6A06-4752-8F6F-F6442115BCC9Q43460633-6089BF29-1FAC-4612-BD0B-FD01DDB88FF2Q58783846-958A1EDC-25B0-427E-A21B-33E6A146C093
P2860
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
@ast
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
@en
type
label
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
@ast
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
@en
prefLabel
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
@ast
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
@en
P2093
P2860
P356
P1476
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
@en
P2093
Andrea Worschech
Francesco M Marincola
Kamar Godder
Maciej Kmieciak
Madhu Gowda
Maria-Libera Ascierto
Masoud H Manjili
P2860
P2888
P356
10.1186/1479-5876-9-170
P577
2011-10-06T00:00:00Z
P5875
P6179
1015632940